Trends Immunol. 2025 Jul 12:S1471-4906(25)00171-1. doi: 10.1016/j.it.2025.07.004. Online ahead of print.
ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a life-threatening neurodegenerative disease caused by motor neuron loss. In a recent Phase 2b trial, Bensimon and colleagues report that the addition of low-dose interleukin 2 (LD-IL-2) immunotherapy to standard of care (SOC) shows promise in enhancing immune tolerance and improving survival in individuals with slower disease progression.
PMID:40653411 | DOI:10.1016/j.it.2025.07.004